Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: A critical review

Patient Preference and Adherence

Volumn 8, Issue , 2014, Pages 1051-1059

  Besada, Emilio ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Efficacy; Pharmacokinetic; Rheumatoid arthritis; Safety; Subcutaneous; Tocilizumab

Indexed keywords

CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; TOCILIZUMAB; TUMOR NECROSIS FACTOR;

AREA UNDER THE CURVE; AUTOIMMUNITY; BODY WEIGHT; BRONCHITIS; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; DYSLIPIDEMIA; HERPES ZOSTER; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; JAPANESE (PEOPLE); LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; MONOTHERAPY; NEUTROPENIA; PATIENT ATTITUDE; PNEUMONIA; POLYPHARMACY; PYELONEPHRITIS; REVIEW; RHEUMATOID ARTHRITIS; TOXIC HEPATITIS; TREATMENT RESPONSE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 84905586060     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S34958     Document Type: Review

References (38)

1. Davis JM III, Matteson EL. American College of Rheumatology, European League Against Rheumatism. My treatment approach to rheumatoid arthritis. Mayo Clin Proc. 2012; 87(7): 659-673.
2. Allaire S, Wolfe F, Niu J, Lavalley MP. Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US. Arthritis Rheum. 2008; 59(4): 474-480.
3. Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. 2003; 48(1): 54-58.
4. Aletaha D, Neogi T, Silman AJ, el al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62(9): 2569-2581.
5. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010; 69(4): 631-637.
6. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014; 73(3): 492-509.
7. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro-and anti-inflammatory properties of the cytokine interleukine-6. Biochim Biophys Acta. 2011; 1813(5): 878-888.
8. Ash Z, Emery P. The role of tocilizumab in the management of rheumatoid arthritis. Expert Opin Biol Ther. 2012; 12(9): 1277-1289.
9. Alten R, Maleitzke T. Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic disease. Ann Med. 2013; 45(4): 357-363.
10. Schiff M. Subcutaneous abatacept for the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2013; 52(6): 986-997.
11. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukine-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008; 112(10): 3959-3964.
12. Ohta S, Tsuru T, Terao K, et al. Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study). J Clin Pharmacol. 2014; 54(1): 109-119.
13. roche-trials. com [homepage on the internet]. F. Hoffman-La Roche Ltd. Clinical trial result information: protocol number NA25220. ClinicalTrials. gov identifier NCT 01232569. Available from http:// www. roche-trials. com/studyResultGet. action?studyResultNumber=NA25220. Accessed February 1, 2014.
14. Kivitz A, Olech E, Borofsky MA, et al. The safety and efficacy of tocilizumab subcutaneous in combination with traditional DMARDS in patients with moderate to severe rheumatoid arthritis up to 48 weeks (BREVACTA). Arthritis Rheum. 2013; 65: s604-s605.
15. Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis. 2014; 73(1): 69-74.
16. Ogata A, Tanimura K, Sugimoto T, et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014; 66(3): 344-354.
17. Nishimoto N, Miyasaka N, Yamammoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009; 19(1): 12-19.
18. Al-Shakarchi I, Gullick NJ, Scott DL. Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review. Patient Prefer Adherence. 2013; 7: 653-666.
19. Schoels MM, van der Heijde D, Breedveld FC, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis. 2013; 72(4): 583-589.
20. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013; 72(1): 43-50.
21. Byberk VP, Östör AJK, Alvaro-Gracia J, et al. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann Rheum Dis. 2012; 71(12): 1950-1954.
22. Weinblatt ME, Kremer J, Cush J, et al. Tocilizumab monotherapy or in combination with non-biologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study. Arthritis Care Res (Hoboken). 2013; 65(3): 362-371.
23. Nishimoto N, Miyasaka N, Yamomoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2009; 68(10): 1580-1584.
24. Nishimoto N, Amano K, Hirabayashi Y, et al. Drug free remission/low disease activity after cessation of tocilizumab (Actemra) monotherapy (DREAM) study. Mod Rheumatol. 2014; 24(1): 17-25.
25. Leffers HC, Østergaard M, Glintborg B, et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis. 2011; 70(7): 1216-1222.
26. Smolen JS, Martinez Avila JC, Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis. 2012; 71(5): 687-693.
27. Schiff MH, Kremer JM, Jahres A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011; 13(5): R141.
28. Campbell L, Chen C, Bhagat SS, Parker RA, Ostor AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2011; 50(3): 552-562.
29. Gómez-Reino J. Biologics monotherapy as initial treatment in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2012; 51 Suppl 5: 31-37.
30. Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised double-blind, controlled phase 4 trial. Lancet. 2013; 381(9877): 1541-1550.
31. Das S, Vital EM, Horton S, et al. Abatacept or tocilizumab after rituximab arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Ann Rheum Dis. 2014; 73(5): 909-912.
32. Choquette D, Arundine M, Thomas O. Large discrepancy between expected and observed ratios of biologic treated rheumatoid arthritis patients also compliant on DMARDS. Ann Rheum Dis. 2011; 70: 197.
33. Emery P, Sebba A, Huizinga TW. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis. 2013; 72(12): 1897-1904.
34. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview (review). Cochrane Database Syst Rev. 2011; 16(2): CD008794.
35. Schellekens H. The immunogenicity of therapeutic proteins. Discov Med. 2010; 9(49): 560-564.
36. Favalli EG, Biggioggero M, Marchesoni A, Meroni PL. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford). Epub 2014 Apr 12.
37. Golmia RP, Scheinberg MA. Retention rates of infliximab and tocilizumab during a 3-year period in a Brazilian hospital. Einstein (Sao Paulo). 2013; 11(4): 492-494.
38. Nishimoto N, Amano K, Hirabayashi Y, et al. Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study. Mod Rheumatol. 2014; 24(1): 26-32.